
VRAX
Healthcare · Biotechnology · $823,939 market cap
$0.6126-0.06 (-8.3%)Nov 13, 4:04 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 2, 2025 | Time not confirmed | — | -0.49 | — |
| Jul 2, 2025 | Time not confirmed | — | -0.76 | — |
| Nov 20, 2024 | Time not confirmed | — | -0.89 | — |
| Jul 21, 2022 | Time not confirmed | — | -0.03 | — |
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic…